✨ Health Notices
Health
Human Assisted Reproductive Technology Act 2004
Guidelines Issued and Advice Given to the Ethics Committee on Assisted Reproductive Technology
Pursuant to sections 35 and 36 of the Human Assisted Reproductive Technology Act 2004 (“the HART Act”), the Advisory Committee on Assisted Reproductive Technology (ACART) has issued amended and renamed Guidelines on Surrogacy involving Assisted Reproductive Procedures and amended Guidelines on Donation of Eggs or Sperm between Certain Family Members to the Ethics Committee on Assisted Reproductive Technology (ECART) to come into effect from Monday 16 December 2013.
Pursuant to section 35 of the HART Act, ACART has also given updated and renamed advice to ECART on Applications that fall under more than one of the guidelines issued by ACART.
Pursuant to section 36(2) of the HART Act, the amended guidelines, with the amended advice, are available online at www.acart.health.govt.nz from Monday 16 December 2013.
Copies are also available from the ACART Secretariat at PO Box 5013, Wellington 6145. Telephone: (04) 816 3931. Email: acart@moh.govt.nz
Dated at Lowburn this 10th day of December 2013.
JOHN ANGUS, Chair, Advisory Committee on Assisted Reproductive Technology.
go8000
Medicines Act 1981
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Cisatracurium-AFT
- Active Ingredient: Cisatracurium besilate 0.268%w/v equivalent to Cisatracurium 0.2%w/v
- Dosage Form: Solution for injection
- New Zealand Sponsor: AFT Pharmaceuticals Limited
- Manufacturer: Pharmathen SA, Attiki, Greece
Product: Cisatracurium-AFT
- Active Ingredient: Cisatracurium besilate 0.669%w/v equivalent to Cisatracurium 0.5%w/v
- Dosage Form: Solution for injection
- New Zealand Sponsor: AFT Pharmaceuticals Limited
- Manufacturer: Pharmathen SA, Attiki, Greece
Product: Neutrogena T/Sal Therapeutic Shampoo
- Active Ingredient: Salicylic acid 3%
- Dosage Form: Shampoo
- New Zealand Sponsor: Johnson & Johnson (New Zealand) Limited
- Manufacturer: Neutrogena Corporation, California, United States of America
Product: Relvar® Ellipta®
- Active Ingredients:
- Fluticasone furoate 100mcg
- Vilanterol trifenatate 40mcg equivalent to Vilanterol 25mcg
- Dosage Form: Powder for inhalation
- New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
- Manufacturer: Glaxo Operations UK Limited (t/a Glaxo Wellcome Operations), Hertfordshire, United Kingdom
Product: Relvar® Ellipta®
- Active Ingredients:
- Fluticasone furoate 200mcg
- Vilanterol trifenatate 40mcg equivalent to Vilanterol 25mcg
- Dosage Form: Powder for inhalation
- New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
- Manufacturer: Glaxo Operations UK Limited (t/a Glaxo Wellcome Operations), Hertfordshire, United Kingdom
Dated this 5th day of December 2013.
CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
go7866
Next Page →
✨ LLM interpretation of page content
🏥 Amended Guidelines on Surrogacy and Egg/Sperm Donation
🏥 Health & Social Welfare10 December 2013
Surrogacy, Egg Donation, Sperm Donation, HART Act, ACART, ECART
- JOHN ANGUS, Chair, Advisory Committee on Assisted Reproductive Technology
🏥 Consent to Distribution of New Medicines
🏥 Health & Social Welfare5 December 2013
Medicines, Distribution, Cisatracurium-AFT, Neutrogena T/Sal, Relvar Ellipta, Medsafe
- CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health
NZ Gazette 2013, No 167